Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer

McPhail, 2015, Stage at diagnosis and early mortality from cancer in England, Br. J. Cancer, 112, S108, 10.1038/bjc.2015.49 Tørring, 2013, Evidence of increasing mortality with longer diagnostic intervals for five common cancers: A cohort study in primary care, Eur. J. Cancer, 49, 2187, 10.1016/j.ejca.2013.01.025 Bislev, 2015, Prevalence of cancer in Danish patients referred to a fast-track diagnostic pathway is substantial, Dan. Med. J., 62, 1 Ingeman, 2015, The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer-a cross-sectional study of patient characteristics and cancer probability, BMC Cancer, 15, 421, 10.1186/s12885-015-1424-5 Lebech, 2017, Whole-body 18 F-FDG PET/CT is superior to CT as first-line diagnostic imaging in patients referred with serious nonspecific symptoms or signs of cancer: a randomized prospective study of 200 patients, J. Nucl. Med., 58, 1058, 10.2967/jnumed.116.175380 Rasmussen, 2017, Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer, Int. J. Cancer, 141, 191, 10.1002/ijc.30732 Mustjoki, 2000, Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy, Cancer Res., 60, 7126 Jing, 2012, Evaluating the value of uPAR of serum and tissue on patients with cervical cancer, J. Clin. Lab. Anal., 26, 16, 10.1002/jcla.20499 Riisbro, 2002, Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer, Clin. Cancer Res., 8, 1132 Usnarska-Zubkiewicz, 2014, Soluble urokinase-type plasminogen activator receptor and Ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease – preliminary report, Adv. Clin. Exp. Med., 23, 959, 10.17219/acem/30817 Chounta, 2015, Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma, Liver Int., 35, 601, 10.1111/liv.12705 Wach, 2015, The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer, Int. J. Cancer, 137, 1406, 10.1002/ijc.29505 Schmidt, 1999, Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients, Acta Otolaryngol., 119, 949, 10.1080/00016489950180342 Loosen, 2019, High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma, Carcinogenesis, 10.1093/carcin/bgz033 Loosen, 2018, Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases, Oncotarget., 9, 27027, 10.18632/oncotarget.25471 Rasmussen, 2018, Combining national early warning score with soluble urokinase plasminogen activator receptor (suPAR) improves risk prediction in acute medical patients, Crit. Care Med., 46, 1961, 10.1097/CCM.0000000000003441 Liu, 2017, Prognostic role of circulating soluble uPAR in various cancers: a systematic review and meta-analysis, Clin Lab., 63, 871 Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J. Natl Cancer Inst., 101, 1446, 10.1093/jnci/djp335 The Danish Health Authority. Diagnostisk pakkeforløb for patienter med uspecifikke symptomer på alvorlig sygdom, der kunne være kræft [The Cancer Patient Pathway for serious non-specific symptoms and signs of cancer] (report in Danish). 2016. https://www.sst.dk/da/sygdom-og-behandling/kraeft/pakkeforloeb/~/media/3AACA5B705B44EAF84F62B9FBB16AC7A.ashx. E. Lynge, J.L. Sandegaard, M. Rebolj, The Danish National Patient Register. Scand J Public Health. 2011;39(7_suppl):30-33. doi: 10.1177/1403494811401482. M.L. Gjerstorff, The Danish Cancer Registry. Scand. J. Public Health. 2011;39(7_suppl):42-45. doi: 10.1177/1403494810393562. Haupt, 2014, Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population, Biomark Insights, 9, 91, 10.4137/BMI.S19876 Youden, 1950, Index for rating diagnostic tests, Cancer, 3, 32, 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 Rasmussen, 2016, Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study, Emerg. Med. J., 33, 769, 10.1136/emermed-2015-205444 Schmidt, 2015, The Danish National patient registry: a review of content, data quality, and research potential, Clin. Epidemiol., 7, 449, 10.2147/CLEP.S91125 Haupt, 2019, Healthy lifestyles reduce suPAR and mortality in a Danish general population study, Immun. Ageing, 16, 1, 10.1186/s12979-018-0141-8